How biopharma leaders are balancing capital scarcity, milestone-based deals, and the promise of AI to boost R&D productivity and attract investor capital.
AI, Capital, and Partnering: New Imperatives for Biotech C-Suites Read More »
WhiteLab Genomics secured $26M Series B to expand ALFRED, its AI platform creating IP-protected gene delivery ‘bio-assets’ that cross the blood-brain barrier and will be licensed to biopharma partners.
WhiteLab Genomics Raises $26M to Scale AI-Designed Gene Delivery Read More »
AGENT AI used Bayesian optimization to produce mRNA-LNP formulations stable at room temperature for months, removing cold-chain limits and enabling decentralized trials.
AI’s Breakthrough: Ending the Cold Chain for mRNA Vaccines Read More »
Anthropic expands verified access to advanced AI for life sciences and reports Claude-driven speedups in biomolecular modeling, raising governance and biosecurity questions.
Anthropic’s Dual Leap: Controlled Access and Faster Biomolecular Modeling with Claude Read More »
Assess whether AI is delivering measurable value in biotech. Evidence from drug discovery, clinical trials, investment trends, and how to spot substantive AI companies.
AI in Biotech: Real Growth or Hype? A Practical Read for Investors and Researchers Read More »
North Rhine-Westphalia is investing €200M in AI4CancerCure.NRW to unite university hospitals and TU Dortmund, advancing AI-driven drug design, diagnostics and precision oncology.
Adaptyv closed a $40M Series A led by Highland Europe to expand agentic biology and automated wet labs, closing the gap between AI design and physical testing.
Adaptyv Raises $40M to Scale Agentic Biology and Automated Wet Labs Read More »
MassBio data and industry signals show a funding gap: investors prefer later-stage biotech. What this means for AI-driven biotech startups and funding strategy.
AI Biotech Funding Trends: Why Seed Starts Are Squeezed While Series A Soars Read More »
AI is accelerating drug discovery, gene editing, and synthetic biology faster than rules can adapt. A risk-tiered, adaptive governance model is needed.
AI and Biotechnology: Regulating the Convergence Read More »
Stanford deployed 37,000 AI agents to create a ‘virtual biotech’ that simulates research teams, analyzes clinical trials and speeds identification of therapeutic strategies.
Stanford’s AI Agents Form a Virtual Biotech: A New Era in Drug Discovery Read More »
